

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Henrike Lotz

Serial No.: 10/593,213

Filed: January 12, 2007

For: HYPHAE-SPECIFIC CELL WALL PROTEINS OF CANDIDA

Confirmation No.: 5911

Date: April 16, 2009

Group Art Unit: 1656

Examiner: Marsha M. Tsay

VIA EFS - WEB

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

APPLICANTS' STATEMENT OF THE SUBSTANCE OF THE INTERVIEW


Sir:

In response to the Interview Summary mailed on April 8, 2009 which requires the applicants to file a Statement of the Substance of the Interview, the required statement follows.

Applicants' representative conducted a telephonic interview with the Examiner on April 6, 2009 (not on December 30, 1899 as indicated on the Interview Summary form) in which the species requirement regarding claim 22 (on p. 4 of the Restriction Requirement dated March 16, 2009) was discussed. The Examiner clarified that the species requirement was meant to be between the pathogenic fungal species of *Trichosporon* and *Blastoschizomyces* and that the *Candida* species would be included notwithstanding which of the two pathogenic fungal species was elected. Per this clarification, the applicants elected *Candida* and *Trichosporon* in the "Response to Restriction and Election Requirements" that was electronically filed on April 10, 2009.

Respectfully submitted,

THIS CORRESPONDENCE IS BEING
SUBMITTED ELECTRONICALLY THROUGH
THE PATENT AND TRADEMARK OFFICE
EFS FILING SYSTEM ON April 16, 2009.



Mark A. Farley

Registration No.: 33,170

OSTROLENK, FABER, GERB & SOFFEN, LLP

1180 Avenue of the Americas

New York, New York 10036-8403

Telephone: (212) 382-0700

MAF:stb